| Literature DB >> 24633243 |
E-Chiang Lee1, Qi Liang1, Hanif Ali1, Luke Bayliss1, Alastair Beasley1, Tara Bloomfield-Gerdes1, Laura Bonoli1, Richard Brown1, Jamie Campbell1, Adam Carpenter1, Sara Chalk1, Alison Davis1, Nick England1, Alla Fane-Dremucheva1, Bettina Franz1, Volker Germaschewski1, Helen Holmes1, Steve Holmes1, Ian Kirby1, Miha Kosmac1, Anais Legent1, Hui Lui1, Anais Manin1, Siobhan O'Leary1, Jemima Paterson1, Rocco Sciarrillo1, Anneliese Speak2, Dominik Spensberger1, Laura Tuffery1, Nikole Waddell1, Wei Wang2, Sophie Wells1, Vivian Wong1, Andrew Wood1, Michael J Owen1, Glenn A Friedrich1, Allan Bradley3.
Abstract
If immunized with an antigen of interest, transgenic mice with large portions of unrearranged human immunoglobulin loci can produce fully human antigen-specific antibodies; several such antibodies are in clinical use. However, technical limitations inherent to conventional transgenic technology and sequence divergence between the human and mouse immunoglobulin constant regions limit the utility of these mice. Here, using repetitive cycles of genome engineering in embryonic stem cells, we have inserted the entire human immunoglobulin variable-gene repertoire (2.7 Mb) into the mouse genome, leaving the mouse constant regions intact. These transgenic mice are viable and fertile, with an immune system resembling that of wild-type mice. Antigen immunization results in production of high-affinity antibodies with long human-like complementarity-determining region 3 (CDR3H), broad epitope coverage and strong signatures of somatic hypermutation. These mice provide a robust system for the discovery of therapeutic human monoclonal antibodies; as a surrogate readout of the human antibody response, they may also aid vaccine design efforts.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24633243 DOI: 10.1038/nbt.2825
Source DB: PubMed Journal: Nat Biotechnol ISSN: 1087-0156 Impact factor: 54.908